Literature DB >> 20626511

Effects of diabetes mellitus on VEGF-induced proliferation response in bone marrow derived endothelial progenitor cells.

Shigetoshi Mieno1, Munir Boodhwani, Michael P Robich, Richard T Clements, Neel R Sodha, Frank W Sellke.   

Abstract

BACKGROUND: This study examined effects of diabetes mellitus (DM) on cellular proliferation associated with vascular endothelial growth factor (VEGF) signaling in endothelial progenitor cells (EPCs) and evaluated protein expression involved in cellular proliferation and proapoptotic signaling in chronically ischemic myocardium.
METHODS: Insulin-dependent DM was induced in yucatan miniswine with alloxan. Eight weeks after induction, chronic ischemia was induced by ameroid constrictor placement around the circumflex coronary artery. Seven weeks after ameroid constrictor, perfusion of ischemic territory was measured by isotope-labeled microspheres, and ischemic myocardium was harvested. Bone marrow (BM) samples were harvested from iliac bone and mononuclear cells (MNCs) were cryopreserved. EPCs were isolated from cryopreserved MNCs in control (n = 6) and DM swine (n = 6). EPC proliferation was assessed.
RESULTS: EPC proliferation was decreased in DM as compared to control (1.02 ± 0.09, 0.40 ± 0.04, p < 0.01). VEGF-induced EPC proliferation was impaired in DM as compared to control (p < 0.01). Expression of ERK protein, an activator of VEGF-induced cell proliferation, was decreased. AKT activation, an inhibitor of apoptosis, was decreased, while Bad, an activator of proapoptotic signaling, was elevated in the ischemic myocardium from DM. Collateral dependent perfusion was impaired in DM.
CONCLUSION: Impaired VEGF-induced proliferation response in EPC as well as an increase in negative myocardial protein expression for cell proliferation and proapoptotic signaling via VEGF could be a therapeutic target to enhance the effects of proangiogenesis therapies in DM and other chronic illnesses.
© 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20626511      PMCID: PMC2958227          DOI: 10.1111/j.1540-8191.2010.01086.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  30 in total

1.  Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial.

Authors:  Kai C Wollert; Gerd P Meyer; Joachim Lotz; Stefanie Ringes-Lichtenberg; Peter Lippolt; Christiane Breidenbach; Stephanie Fichtner; Thomas Korte; Burkhard Hornig; Diethelm Messinger; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler
Journal:  Lancet       Date:  2004 Jul 10-16       Impact factor: 79.321

2.  Effects of L-arginine on the endogenous angiogenic response in a model of hypercholesterolemia.

Authors:  Yasunari Nakai; Pierre Voisine; Cesario Bianchi; Shu-Hua Xu; Jun Feng; Tamer Malik; Audrey Rosinberg; Frank W Sellke
Journal:  Surgery       Date:  2005-08       Impact factor: 3.982

3.  Analysis of cord blood CD34+ cells purified after cryopreservation.

Authors:  A Nicol; M Nieda; C Donaldson; P Denning-Kendall; B Bradley; J Hows
Journal:  Exp Hematol       Date:  1995-12       Impact factor: 3.084

4.  Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease.

Authors:  Tiffany M Powell; Jonathan D Paul; Jonathan M Hill; Michael Thompson; Moshe Benjamin; Maria Rodrigo; J Philip McCoy; Elizabeth J Read; Hanh M Khuu; Susan F Leitman; Toren Finkel; Richard O Cannon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-11-29       Impact factor: 8.311

5.  Normalization of coronary microvascular reactivity and improvement in myocardial perfusion by surgical vascular endothelial growth factor therapy combined with oral supplementation of l-arginine in a porcine model of endothelial dysfunction.

Authors:  Pierre Voisine; Cesario Bianchi; Tanveer A Khan; Marc Ruel; Shu-Hua Xu; Jun Feng; Jian Li; Tamer Malik; Audrey Rosinberg; Frank W Sellke
Journal:  J Thorac Cardiovasc Surg       Date:  2005-06       Impact factor: 5.209

6.  High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis.

Authors:  B Millauer; S Wizigmann-Voos; H Schnürch; R Martinez; N P Møller; W Risau; A Ullrich
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

7.  Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells.

Authors:  Alexandra Aicher; Christopher Heeschen; Christiane Mildner-Rihm; Carmen Urbich; Christian Ihling; Katja Technau-Ihling; Andreas M Zeiher; Stefanie Dimmeler
Journal:  Nat Med       Date:  2003-10-12       Impact factor: 53.440

8.  Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential.

Authors:  Tae-Wook Chung; Young-Choon Lee; Cheorl-Ho Kim
Journal:  FASEB J       Date:  2004-05-07       Impact factor: 5.191

9.  Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells.

Authors:  Jun Cai; Shakil Ahmad; Wen G Jiang; Jianhua Huang; Christopher D Kontos; Mike Boulton; Asif Ahmed
Journal:  Diabetes       Date:  2003-12       Impact factor: 9.461

10.  Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase.

Authors:  Ulf Landmesser; Niels Engberding; Ferdinand H Bahlmann; Arnd Schaefer; Antje Wiencke; Andre Heineke; Stephan Spiekermann; Denise Hilfiker-Kleiner; Christian Templin; Daniel Kotlarz; Maja Mueller; Martin Fuchs; Burkhard Hornig; Hermann Haller; Helmut Drexler
Journal:  Circulation       Date:  2004-10-05       Impact factor: 29.690

View more
  7 in total

1.  Exercise increases serum endostatin levels in female and male patients with diabetes and controls.

Authors:  Michael Sponder; Daniela Dangl; Stephanie Kampf; Monika Fritzer-Szekeres; Jeanette Strametz-Juranek
Journal:  Cardiovasc Diabetol       Date:  2014-01-06       Impact factor: 9.951

2.  High glucose impairs the proliferation and increases the apoptosis of endothelial progenitor cells by suppression of Akt.

Authors:  Nobuhisa Nakamura; Keiko Naruse; Yasuko Kobayashi; Takashi Matsuki; Yoji Hamada; Eitaro Nakashima; Hideki Kamiya; Masaki Hata; Toru Nishikawa; Atsushi Enomoto; Masahide Takahashi; Toyoaki Murohara; Tatsuaki Matsubara; Yutaka Oiso; Jiro Nakamura
Journal:  J Diabetes Investig       Date:  2011-08-02       Impact factor: 4.232

3.  MMP-sensitive PEG hydrogel modified with RGD promotes bFGF, VEGF and EPC-mediated angiogenesis.

Authors:  Liu Ouyang; Yang Dan; Zengwu Shao; Shuhua Yang; Cao Yang; Guohui Liu; Deyu Duan
Journal:  Exp Ther Med       Date:  2019-08-13       Impact factor: 2.447

4.  Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K/Akt and NF-κB/MMP-2 signaling pathways.

Authors:  Yajuan Su; Lingjuan Gao; Lichen Teng; Ying Wang; Jialin Cui; Shiyun Peng; Songbin Fu
Journal:  J Transl Med       Date:  2013-05-29       Impact factor: 5.531

5.  Erythropoietin attenuates cardiac dysfunction by increasing myocardial angiogenesis and inhibiting interstitial fibrosis in diabetic rats.

Authors:  Jing Lu; Yu-yu Yao; Qi-ming Dai; Gen-shan Ma; Shu-feng Zhang; Lei Cao; Li-qun Ren; Nai-feng Liu
Journal:  Cardiovasc Diabetol       Date:  2012-09-07       Impact factor: 9.951

Review 6.  Intracavernous administration of bone marrow mononuclear cells: a new method of treating erectile dysfunction?

Authors:  Thomas E Ichim; Timothy Warbington; Octav Cristea; Joseph L Chin; Amit N Patel
Journal:  J Transl Med       Date:  2013-06-09       Impact factor: 5.531

7.  Z-Ligustilide Ameliorates Diabetic Rat Retinal Dysfunction Through Anti-Apoptosis and an Antioxidation Pathway.

Authors:  Bing Yang; Guobin Ma; Yang Liu
Journal:  Med Sci Monit       Date:  2020-10-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.